Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.
Anneke D van DijkFieke W HoffYihua QiuRobert B GerbingAlan S GamisRichard AplencE Anders KolbTodd A AlonzoSoheil MeshinchiGaye N JenkinsEveline S J M de BontSteven M KornblauTerzah M HortonPublished in: Proteomics. Clinical applications (2021)
Bortezomib may improve clinical outcome in a subgroup of AML patients identified by low-RelA-pSer536 and low-HSF1-pSer326 .
Keyphrases
- newly diagnosed
- acute myeloid leukemia
- end stage renal disease
- multiple myeloma
- ejection fraction
- chronic kidney disease
- signaling pathway
- prognostic factors
- peritoneal dialysis
- allogeneic hematopoietic stem cell transplantation
- clinical trial
- immune response
- lps induced
- inflammatory response
- acute lymphoblastic leukemia